Tom 14, Nr 6 (2019)
Artykuł redakcyjny
Opublikowany online: 2019-12-31
Wyświetlenia strony
422
Wyświetlenia/pobrania artykułu
387
Od Redaktora
DOI: 10.5603/FC.2019.0118
Folia Cardiologica 2019;14(6).
Streszczenie
Brak
Referencje
- Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Centrum Onkologii — Instytut im. Marii Skłodowskiej-Curie. http://onkologia.org (2018).
- Montgomery DA, Krupa K, Cooke TG. Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature. Br J Cancer. 2007; 97(12): 1632–1641.
- McTiernan A. Behavioral risk factors in breast cancer: can risk be modified? Oncologist. 2003; 8(4): 326–334.
- Charakterystyka produktu leczniczego rybocyklib — Kisquali. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_pl.pdf (14.02.2020).
- Choroby onkologiczne — Ministerstwo Zdrowia. https://www.gov.pl/web/zdrowie/choroby-onkologiczne (2019).
- Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016; 375(18): 1738–1748.
- Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018; 36(24): 2465–2472.
- Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018; 19(7): 904–915.
- Im S-A, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019; 381(4): 307–316.
- Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020; 382(6): 514–524.
- A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE). https://clinicaltrials.gov/ct2/show/NCT03701334?cond=natalee&draw=1&rank=1 (14.02.2020).
- Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer (CORALLEEN). https://clinicaltrials.gov/ct2/show/NCT03248427 (14.02.2020).
